Header Logo

William Towner

Concepts (263)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
HIV Infections
44
2023
704
3.980
Why?
Anti-HIV Agents
23
2023
159
2.770
Why?
HIV-1
14
2015
73
1.780
Why?
Pyridazines
5
2010
6
0.920
Why?
CD4 Lymphocyte Count
20
2022
181
0.880
Why?
Viral Load
16
2018
136
0.880
Why?
Antiviral Agents
7
2020
94
0.870
Why?
Reverse Transcriptase Inhibitors
7
2013
25
0.810
Why?
Adult
49
2023
7658
0.790
Why?
Antiretroviral Therapy, Highly Active
11
2017
94
0.730
Why?
Hepatitis C, Chronic
7
2015
64
0.710
Why?
Male
49
2023
10094
0.670
Why?
Humans
62
2023
17707
0.650
Why?
Middle Aged
40
2023
7976
0.620
Why?
Female
48
2023
12729
0.600
Why?
Electronics, Medical
1
2018
3
0.590
Why?
Hepacivirus
7
2015
52
0.570
Why?
Carbamates
6
2015
8
0.560
Why?
Acquired Immunodeficiency Syndrome
3
2017
63
0.540
Why?
Sofosbuvir
5
2015
5
0.540
Why?
Heterocyclic Compounds, 4 or More Rings
4
2015
4
0.510
Why?
Cohort Studies
21
2023
2589
0.490
Why?
Treatment Outcome
19
2020
1254
0.480
Why?
Hepatitis B
3
2022
42
0.470
Why?
California
19
2018
2327
0.450
Why?
Pyrrolidinones
3
2014
4
0.440
Why?
Hepatitis B Vaccines
4
2023
43
0.440
Why?
Electronic Health Records
1
2018
694
0.400
Why?
Liver Diseases
1
2012
23
0.400
Why?
Anti-Retroviral Agents
6
2015
80
0.390
Why?
Young Adult
15
2018
2450
0.370
Why?
HIV Envelope Protein gp41
3
2010
4
0.370
Why?
Myocardial Infarction
3
2022
234
0.370
Why?
Peptide Fragments
3
2010
27
0.360
Why?
Raltegravir Potassium
4
2018
9
0.350
Why?
Drug Resistance, Viral
7
2015
12
0.340
Why?
Aged
21
2020
6150
0.320
Why?
Life Expectancy
2
2020
33
0.300
Why?
Neoplasms
4
2015
442
0.280
Why?
Exercise Therapy
2
2019
71
0.270
Why?
Prenatal Care
1
2008
129
0.270
Why?
Pregnancy Complications, Infectious
1
2008
147
0.260
Why?
RNA, Viral
8
2015
65
0.260
Why?
Hospitalization
4
2023
805
0.260
Why?
Ritonavir
4
2010
14
0.260
Why?
Pulmonary Disease, Chronic Obstructive
2
2019
196
0.250
Why?
HIV
2
2017
26
0.240
Why?
Sulfonamides
4
2014
15
0.240
Why?
Dideoxynucleosides
3
2016
8
0.230
Why?
Vaccination
3
2020
656
0.230
Why?
Emergency Service, Hospital
2
2019
377
0.220
Why?
Adolescent
8
2018
3671
0.220
Why?
Risk Factors
11
2016
3367
0.220
Why?
Anaphylaxis
1
2023
16
0.210
Why?
Thrombosis
1
2023
11
0.210
Why?
Drug Therapy, Combination
8
2015
115
0.210
Why?
Fractures, Bone
1
2023
95
0.200
Why?
Genotype
7
2015
227
0.200
Why?
Lymphoma, AIDS-Related
3
2011
18
0.200
Why?
Herpes Zoster Vaccine
1
2023
59
0.200
Why?
Risk
3
2020
517
0.200
Why?
Incidence
7
2016
1269
0.200
Why?
Mutation
3
2012
131
0.190
Why?
Herpes Zoster
1
2023
82
0.190
Why?
Case-Control Studies
5
2020
1117
0.190
Why?
Patient Compliance
4
2014
299
0.190
Why?
HIV Protease Inhibitors
3
2010
24
0.190
Why?
HIV Reverse Transcriptase
2
2012
2
0.180
Why?
Pre-Exposure Prophylaxis
1
2021
19
0.180
Why?
Treatment Adherence and Compliance
1
2020
12
0.180
Why?
Oligopeptides
3
2010
6
0.170
Why?
Pyridines
3
2010
9
0.170
Why?
Adenosine Monophosphate
1
2020
4
0.170
Why?
Alanine
1
2020
6
0.170
Why?
HIV Protease
2
2010
4
0.170
Why?
Coronavirus Infections
1
2020
48
0.160
Why?
Delivery of Health Care, Integrated
2
2018
531
0.160
Why?
Pneumonia, Viral
1
2020
55
0.160
Why?
Mentoring
1
2019
26
0.160
Why?
Walking
2
2019
86
0.160
Why?
African Continental Ancestry Group
2
2016
162
0.150
Why?
Retrospective Studies
7
2023
2471
0.150
Why?
Aged, 80 and over
7
2019
1927
0.150
Why?
Product Surveillance, Postmarketing
1
2018
95
0.150
Why?
Tablets
1
2017
2
0.140
Why?
Common Variable Immunodeficiency
1
2017
5
0.140
Why?
Psoriasis
1
2017
9
0.140
Why?
Heart Failure
1
2022
398
0.140
Why?
Organophosphonates
3
2014
7
0.140
Why?
Adenine
3
2014
8
0.140
Why?
Pneumonia
1
2017
51
0.130
Why?
Pneumococcal Infections
1
2016
42
0.130
Why?
Darunavir
3
2010
4
0.130
Why?
Tenofovir
4
2023
18
0.130
Why?
Pneumococcal Vaccines
1
2016
66
0.130
Why?
Quality of Life
2
2019
521
0.130
Why?
Multivariate Analysis
3
2012
561
0.130
Why?
Uridine Monophosphate
1
2015
1
0.120
Why?
Benzimidazoles
1
2015
6
0.120
Why?
Fluorenes
1
2015
5
0.120
Why?
Drug Administration Schedule
4
2020
100
0.120
Why?
Prospective Studies
3
2022
1287
0.120
Why?
Coinfection
1
2015
30
0.120
Why?
Continuity of Patient Care
1
2015
103
0.120
Why?
Isoquinolines
1
2014
1
0.120
Why?
Imidazoles
1
2014
4
0.120
Why?
Lymphoma, Non-Hodgkin
2
2011
24
0.110
Why?
Hepatitis C
1
2015
64
0.110
Why?
Prostate-Specific Antigen
1
2014
75
0.110
Why?
United States
5
2020
3914
0.110
Why?
Health Services Accessibility
1
2016
280
0.110
Why?
RNA-Directed DNA Polymerase
1
2013
3
0.110
Why?
Continental Population Groups
1
2015
301
0.110
Why?
Lung Neoplasms
1
2017
260
0.110
Why?
Patient-Centered Care
1
2015
194
0.110
Why?
Glomerular Filtration Rate
2
2014
154
0.110
Why?
Healthcare Disparities
1
2015
203
0.110
Why?
Registries
3
2012
470
0.100
Why?
Primary Health Care
2
2021
756
0.100
Why?
Protease Inhibitors
1
2012
6
0.100
Why?
Hepatitis B, Chronic
1
2012
27
0.100
Why?
Viremia
1
2012
9
0.100
Why?
Drug Resistance, Multiple, Viral
1
2012
6
0.100
Why?
Health Maintenance Organizations
3
2008
414
0.100
Why?
Managed Care Programs
1
2014
313
0.100
Why?
HIV Seropositivity
1
2012
31
0.100
Why?
Prostatic Neoplasms
1
2014
262
0.100
Why?
Regression Analysis
1
2012
296
0.090
Why?
Liver Cirrhosis
3
2015
35
0.090
Why?
Stroke
1
2014
316
0.090
Why?
Home Care Services
1
2011
24
0.090
Why?
Drug Combinations
3
2015
43
0.090
Why?
Needs Assessment
1
2011
69
0.090
Why?
Health Services Needs and Demand
1
2011
90
0.090
Why?
Cardiovascular Diseases
1
2016
596
0.090
Why?
Ethnic Groups
2
2015
474
0.080
Why?
Fanconi Syndrome
1
2010
5
0.080
Why?
Social Support
3
2019
204
0.080
Why?
AIDS-Related Opportunistic Infections
2
2015
17
0.080
Why?
Quality Assurance, Health Care
1
2011
137
0.080
Why?
Dose-Response Relationship, Drug
1
2010
128
0.080
Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors
1
2011
172
0.080
Why?
Follow-Up Studies
3
2019
1218
0.080
Why?
Drug-Related Side Effects and Adverse Reactions
3
2017
107
0.080
Why?
AIDS Serodiagnosis
1
2008
10
0.080
Why?
Delivery of Health Care
1
2012
397
0.080
Why?
Birth Certificates
1
2008
24
0.080
Why?
Alcoholism
1
2012
332
0.080
Why?
Lamivudine
1
2008
1
0.080
Why?
Randomized Controlled Trials as Topic
1
2010
327
0.070
Why?
Hispanic Americans
2
2015
397
0.070
Why?
Substance-Related Disorders
1
2012
420
0.070
Why?
Serotonin Uptake Inhibitors
1
2008
71
0.070
Why?
Guideline Adherence
1
2008
155
0.070
Why?
Double-Blind Method
3
2015
160
0.070
Why?
Disease Progression
2
2019
266
0.070
Why?
Viral Nonstructural Proteins
2
2015
3
0.060
Why?
Depressive Disorder
1
2008
220
0.060
Why?
Atazanavir Sulfate
3
2010
5
0.060
Why?
Comorbidity
2
2020
590
0.060
Why?
Rivaroxaban
1
2023
8
0.050
Why?
Mexican Americans
1
2003
45
0.050
Why?
Hemorrhage
1
2023
62
0.050
Why?
Herpesvirus 3, Human
1
2023
44
0.050
Why?
Pregnancy
1
2008
1535
0.050
Why?
RNA
1
2022
12
0.050
Why?
Patient Acceptance of Health Care
1
2006
387
0.050
Why?
Outpatients
1
2023
107
0.050
Why?
Anticoagulants
1
2023
128
0.050
Why?
Creatinine
2
2014
65
0.050
Why?
Child
1
2008
2481
0.050
Why?
Least-Squares Analysis
2
2012
15
0.050
Why?
Anus Neoplasms
2
2012
26
0.050
Why?
Medication Adherence
2
2015
245
0.050
Why?
Risk Assessment
2
2017
1106
0.040
Why?
Observational Studies as Topic
1
2020
47
0.040
Why?
Immunization Programs
1
2020
65
0.040
Why?
Oxygen Inhalation Therapy
1
2020
12
0.040
Why?
Age Factors
2
2014
918
0.040
Why?
Epidemiologic Methods
2
2010
80
0.040
Why?
Betacoronavirus
1
2020
34
0.040
Why?
Immunization Schedule
1
2020
122
0.040
Why?
Insurance, Health
1
2020
175
0.040
Why?
Pandemics
1
2020
286
0.040
Why?
Self Report
1
2019
252
0.040
Why?
Los Angeles
2
2011
137
0.040
Why?
Chronic Disease
1
2020
416
0.030
Why?
Serogroup
1
2016
10
0.030
Why?
Streptococcus pneumoniae
1
2016
19
0.030
Why?
Vaccines, Conjugate
1
2016
59
0.030
Why?
Risk Reduction Behavior
1
2016
108
0.030
Why?
Ribavirin
1
2015
8
0.030
Why?
Spirometry
1
2015
65
0.030
Why?
Self Efficacy
1
2015
68
0.030
Why?
Mass Screening
1
2021
667
0.030
Why?
Sex Distribution
1
2015
189
0.030
Why?
Recurrence
1
2015
189
0.030
Why?
Age Distribution
1
2015
246
0.030
Why?
Kaplan-Meier Estimate
1
2015
129
0.030
Why?
Motivation
1
2015
130
0.030
Why?
Survival Analysis
1
2015
216
0.030
Why?
International Cooperation
1
2014
15
0.030
Why?
Administration, Oral
1
2014
84
0.030
Why?
Emtricitabine
1
2014
1
0.030
Why?
Cobicistat
1
2014
1
0.030
Why?
Hepatitis B Antibodies
1
2014
6
0.030
Why?
Quinolones
1
2014
4
0.030
Why?
Serologic Tests
1
2014
6
0.030
Why?
Thiazoles
1
2014
9
0.030
Why?
Deoxycytidine
1
2014
7
0.030
Why?
Hepatitis B Surface Antigens
1
2014
12
0.030
Why?
Hepatitis B virus
1
2014
20
0.030
Why?
Gonorrhea
1
2014
18
0.030
Why?
Chlamydia Infections
1
2014
22
0.030
Why?
Patient Education as Topic
1
2015
212
0.030
Why?
Syphilis
1
2014
17
0.030
Why?
Motor Activity
1
2015
212
0.030
Why?
Microbial Sensitivity Tests
1
2013
8
0.030
Why?
Genotyping Techniques
1
2013
26
0.030
Why?
European Continental Ancestry Group
1
2015
523
0.030
Why?
Aging
1
2014
163
0.030
Why?
Longitudinal Studies
1
2015
717
0.030
Why?
Proportional Hazards Models
1
2015
710
0.030
Why?
SEER Program
1
2012
92
0.030
Why?
Treatment Failure
1
2012
35
0.020
Why?
Nucleosides
1
2012
1
0.020
Why?
Zidovudine
1
2012
1
0.020
Why?
Thymidine
1
2012
2
0.020
Why?
Virus Replication
1
2011
13
0.020
Why?
Sex Factors
1
2014
639
0.020
Why?
Genomics
1
2012
55
0.020
Why?
Patient Advocacy
1
2011
13
0.020
Why?
Phenotype
1
2012
151
0.020
Why?
Insurance Benefits
1
2011
13
0.020
Why?
Body Mass Index
1
2015
970
0.020
Why?
African Americans
1
2014
465
0.020
Why?
Pyrones
1
2010
1
0.020
Why?
Saquinavir
1
2010
1
0.020
Why?
Lopinavir
1
2010
5
0.020
Why?
Pyrimidinones
1
2010
5
0.020
Why?
Indinavir
1
2010
6
0.020
Why?
Nelfinavir
1
2010
4
0.020
Why?
Organophosphates
1
2010
9
0.020
Why?
Exanthema
1
2010
7
0.020
Why?
Program Evaluation
1
2011
222
0.020
Why?
Polymorphism, Genetic
1
2010
63
0.020
Why?
Withholding Treatment
1
2010
26
0.020
Why?
Algorithms
1
2012
237
0.020
Why?
Kidney Function Tests
1
2010
22
0.020
Why?
Carcinoma, Squamous Cell
1
2009
55
0.020
Why?
Socioeconomic Factors
1
2011
626
0.020
Why?
Prognosis
1
2010
613
0.020
Why?
HIV Fusion Inhibitors
1
2007
1
0.020
Why?
Pilot Projects
1
2008
215
0.020
Why?
Time Factors
1
2010
1095
0.020
Why?
Medical Indigency
1
2006
4
0.020
Why?
Confounding Factors (Epidemiology)
1
2006
86
0.020
Why?
Odds Ratio
1
2008
670
0.020
Why?
Logistic Models
1
2008
918
0.020
Why?
AIDS Dementia Complex
1
2003
1
0.010
Why?
Pneumonia, Pneumocystis
1
2003
4
0.010
Why?
Mexico
1
2003
19
0.010
Why?
Life Style
1
2003
332
0.010
Why?
Concepts (263)
Explore
_
Co-Authors (28)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_
-->

© 2025 Kaiser Permanente